Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 53

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 53
---
 I. The principal business address of TCG Crossover GP I, TCG Crossover I and Chen Yu is 705 High St., Palo Alto, CA 94301. |

33

| (8) | Consists of (i) 1,357,168 shares of our Common Stock held directly and (ii) 1,173,456 shares of Common Stock underlying stock options held by Dr. Harris that are exercisable within 60 days of March 31, 2025. |

| (9) | Consists of (i) 427,981 shares of our Common Stock held directly and (ii) 669,986 shares of our Common Stock underlying stock options held by Mr. Bensen that are exercisable within 60 days of March 31, 2025. |

| (10) | Consists of (i) 4,000 shares of our Common Stock held directly and (ii) 4,133 shares of our Common Stock underlying stock options held by Ms. Gulfo that are exercisable within 60 days of March 31, 2025. |

| (11) | Consists of (i) 89,623 shares of our Common Stock held directly and (ii) 115,067 shares of our Common Stock underlying stock options held by Dr. Kaplan that are exercisable within 60 days of March 31, 2025. |

| (12) | Consists of 12,400 shares of our Common Stock underlying stock options held by Dr. Moran that are exercisable within 60 days of March 31, 2025. |

| (13) | Consists of 47,600 shares of Common Stock underlying stock options held by Mr. More that are exercisable within 60 days of March 31, 2025. |

| (14) | Consists of 12,400 shares of Common Stock underlying stock options held by Mr. Rothenberg that are exercisable within 60 days of March 31, 2025. |

| (15) | Consists of 47,600 shares of Common Stock underlying stock options held by Mr. Simson that are exercisable within 60 days of March 31, 2025. Under Mr. Simson’s arrangement with RA Capital, Mr. Simson holds the stock options for the benefit of the Fund, the Nexus Fund and the Account. Mr. Simson is obligated to turn over to RA Capital any net cash or stock received upon exercise